Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Empliciti Market Size And Revenue Forecast Through 2030
The historic expansion was driven by several key factors: a growing number of multiple myeloma cases, the constrained effectiveness of standard chemotherapy, the encouraging initial outcomes from monoclonal antibody therapies, the broader establishment of specialized oncology facilities, and an uptick in funding for cancer research.
The expansion anticipated over the forecast period is driven by increasing uptake of immunotherapy regimens, a broadening array of monoclonal antibody candidates, improved patient survival rates that fuel ongoing treatment needs, supportive reimbursement policies for cancer biologics, and progress in immune-driven drug creation. Key developments shaping this period involve the use of combination monoclonal antibody approaches, cancer therapies aimed at the immune system, a transition toward customized multiple myeloma management, heightened application of immunotherapy in oncology, and rising preference for extended biologic treatment plans.
Download A Free Sample Report For Comprehensive Market Insights:
Empliciti Market Growth Factors Supporting Long-Term Expansion
The growing incidence of multiple myeloma is anticipated to fuel the expansion of the empliciti market in the coming period. Multiple myeloma is a malignancy affecting plasma cells, a category of white blood cells located in bone marrow, resulting in unchecked cell proliferation and potential harm to bones, kidneys, and the immune system. This rise in prevalence is influenced by an aging population and enhanced diagnostic methods. Empliciti acts on the SLAMF7 protein present on myeloma cells and natural killer (NK) cells, strengthening the immune response to identify and destroy cancerous cells. It boosts NK cell function and facilitates antibody-dependent cellular cytotoxicity (ADCC), which slows disease advancement when used alongside other therapies. For example, in August 2024, the American Cancer Society, a nonprofit organization based in the US, reported that roughly 35,780 new multiple myeloma cases were identified in the United States in 2024, comprising 19,520 in men and 16,260 in women. Furthermore, around 12,540 deaths are forecast, with 7,020 in men and 5,520 in women. Hence, the increasing occurrence of multiple myeloma is set to stimulate growth in the empliciti market.
The growing need for targeted cancer therapies is a major factor propelling the expansion of the empliciti market in the future. Targeted cancer therapies are designed to attack cancer cells by recognizing specific molecular signatures, thereby minimizing damage to normal cells. This demand is increasing due to progress in precision medicine, a higher prevalence of cancer, better treatment effectiveness, and a heightened emphasis on reducing side effects. Empliciti focuses on SLAMF7, a protein found on multiple myeloma cells and immune cells, enhancing the body’s immune capability to combat cancer. This combined method improves accuracy while protecting healthy tissues. For instance, in June 2024, as reported by the Royal College of Radiologists, a UK-based professional body overseeing clinical oncology and radiology, the demand for systemic anti-cancer therapies (SACT), including chemotherapy, rose by 6-8% in 2023. Consequently, the increasing demand for targeted cancer therapies will drive the progress of the empliciti market.
Higher healthcare spending is expected to boost the growth of the empliciti market going ahead. Healthcare expenditure refers to the overall funds allocated to health services, encompassing medical procedures, equipment, infrastructure, and staff. This spending is driven by an aging demographic, a greater incidence of chronic illnesses, technological advancements, and an increasing call for improved care. Elevated healthcare expenditure supports investment in advanced cancer treatments such as Empliciti, enabling wider access to innovative therapies. These funds enhance medical infrastructure and foster research, resulting in better cancer care outcomes. For instance, in May 2024, the Office for National Statistics, a UK government agency, noted that total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, a notable increase compared to the 0.9% growth seen in 2022. Thus, rising healthcare expenditure will fuel the expansion of the empliciti market.
Empliciti Market Segmentation Trends And Revenue Drivers
The empliciti market covered in this report is segmented –
1) By Indication: Active Multiple Myeloma, Smoldering Multiple Myeloma
2) By Drug Class: Monoclonal Antibodies, Immunomodulatory Agents, Proteasome Inhibitors
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care
Empliciti Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the empliciti market are Bristol-Myers Squibb Company
Access The Complete Empliciti Market Report:
Empliciti Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the empliciti market in 2025. The regions covered in the empliciti market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model